Tempest Therapeutics (TPST) Operating Expenses (2012 - 2026)

Tempest Therapeutics has disclosed Operating Expenses across 15 years of filings, most recently posting $5.2 million for Q2 2026.

• In Q2 2026, Operating Expenses fell 34.09% year-over-year to $5.2 million; the TTM figure through Jun 2026 stood at $20.9 million (down 51.83% YoY), while the FY2025 annual figure was $26.6 million, down 36.77% from the prior year.
• Operating Expenses came in at $5.2 million for Q2 2026 at Tempest Therapeutics, up from $4.1 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $13.9 million in Q4 2024 to a low of $3.6 million in Q3 2025.
• Average Operating Expenses over 5 years is $8.1 million, with a median of $8.0 million recorded in 2024.
• Year-over-year, Operating Expenses soared 85.23% in 2024 and plunged 70.71% in 2025.
• Over 5 years, Operating Expenses stood at $8.9 million in 2022, then decreased by 15.89% to $7.5 million in 2023, then soared by 85.23% to $13.9 million in 2024, then tumbled by 70.71% to $4.1 million in 2025, then climbed by 28.77% to $5.2 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $5.2 million in Q2 2026, $4.1 million in Q4 2025, and $3.6 million in Q3 2025.